Allurion, a medical device company dedicated to fighting obesity, has signed a pilot collaboration agreement with global medical technology company Medtronic.

The collaboration aims to expand access to Allurion’s AI-powered weight loss programme in the Central and Eastern Europe, Middle East, and Africa (CEMA) region.

Leveraging Medtronic channels, Allurion will offer Allurion Balloon and advance the Allurion Iris AI Platform for the management of bariatric surgery patients.

Allurion founder and CEO Shantanu Gaur said: “We are thrilled to join forces with Medtronic to expand access to our weight loss program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business.

“We also believe this partnership will help accelerate the adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”

Allurion’s weight loss programme combines the Allurion Balloon, a unique swallowable, procedure-less gastric balloon, with the Allurion Virtual Care Suite.

Allurion Virtual Care Suite is a remote patient monitoring solution powered by the Allurion Iris AI Platform and the company’s unique behaviour change programme.

The company offers the suite as a standalone product, to help provide weight loss therapy for patients regardless of their gastric balloon, surgical, medical or nutritional treatment plan.

Earlier this year, Allurion announced its plans to merge with Compute Health, a blank check company, to become a publicly traded company.

Medtronic is currently an investor in Compute Health, and the current partnership builds upon the existing relationship between Medtronic and Compute Health, said Allurion.

Last month, Allurion unveiled results of behavioural science research that could pave the way for the expansion of text- and AI-based coaching.

The study was conducted in the UK and the Netherlands, by Allurion’s Behavioral Science VP Paul Sacher, and Allurion’s psychology director Emily Fulton.